Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of sildenafil and tadalafil, two potent phosphodiesterase type 5 (PDE5) inhibitors, primarily indicated for the treatment of erectile dysfunction. Sildenafil provides a rapid onset of action, typically within 30 to 60 minutes, while tadalafil offers a significantly longer duration of effect, lasting up to 36 hours. This combination is frequently utilized in compounded formulations or specialized delivery formats such as chewable tablets and mints by telehealth providers. In clinical research conducted by Aspargo Labs, these combination products serve as reference comparators for evaluating the pharmacokinetic profile and bioavailability of proprietary liquid sildenafil suspensions like Hezkue (ASP-001) and Hezkue Turbo (ASP-001.1).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sildenafil + tadalafil.